Greater Neighborhood Disadvantage Tied to Inflammatory, Alzheimer Disease Biomarkers
By Elana Gotkine HealthDay Reporter
THURSDAY, July 3, 2025 -- Greater neighborhood disadvantage is associated with increased inflammatory and Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in older adults, according to a study published online June 25 in Neurology.
Marissa A. Gogniat, Ph.D., from the Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined how neighborhood disadvantage relates to core AD pathology, neurodegeneration, and inflammatory biomarkers in community-dwelling older adults who underwent fasting blood and CSF acquisition serially during a nine-year follow-up period. Seventeen components were used to quantify the Area Deprivation Index (ADI), representing neighborhood disadvantage at baseline, with higher values indicating greater disadvantage.
Data were included from 334 participants from relatively less disadvantaged neighborhoods on average (ADI national decile, 33 ± 25). The researchers found a cross-sectional association for greater neighborhood disadvantage at study entry with elevated CSF chitinase-3-like protein 1 and tau (β = 0.7 and 1.8, respectively) after excluding outliers. Faster longitudinal increases in plasma high-sensitivity C-reactive protein were seen in relation to greater neighborhood disadvantage at study entry (β = 0.005).
"We found that greater neighborhood disadvantage was associated with greater levels of tau, a key biomarker of Alzheimer disease," coauthor Angela L. Jefferson, Ph.D., also from Vanderbilt University Medical Center, said in a statement. "This observation suggests that living in more disadvantaged neighborhoods may result in more stressful exposures that drive neurodegeneration, resulting in an increased risk for developing Alzheimer disease."
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.